Read the latest reports on Western Europe, with local insight, sp...
Read the latest reports on Western Europe, with local insight, specialist knowledge and a comprehensive breakdown of key market data. Our research identifies key strategic themes relevant across the region, while also providing a more granular unders...
The pandemic was a boon for NRT smoking cessation aids, as is the ongoing health and wellness trend, with many people trying to give up smoking as COVID-19 put the spotlight on lung health. The category is seeing an increase in both volume and…
Euromonitor International’s Voice of the Consumer: Health and Nutrition Survey, fielded January to February 2023 (n=21,221) indicates that 23.2% of respondents smoked daily, 2.6% once or twice a week, and 1.4% once or twice a month, figures that…
The retail prices of all NRT smoking cessation aids product types have been subject to significant hikes in 2022 and 2023 and this has led to strong growth in value in those years. The penetration of NRT smoking cessation aids in volume terms remains…
The pandemic period led to unhealthier lifestyles for a large number of Irish consumers, with some returning to smoking regular cigarettes as retail outlets selling vapes and other alternatives were closed. The stress and anxiety related to the…
Since the end of the pandemic, smoking prevalence rates have been increasing in Italy, reaching 20% of the population in 2023, up slightly on the previous year. Smoking prevalence fell during the pandemic for several reasons. Firstly, media articles…
Positive volume sales growth returned to NRT smoking cessation aids in 2023 following two years of declining volume during 2022 and 2021. This followed two years of very strong sales growth during 2019 and 2020, when the COVID-19 pandemic encouraged…
NRT smoking cessation aids is projected to post a decline in retail volume sales in 2023, while recording positive retail current value growth. The decline in retail volume sales can be attributed to a couple of key factors. Firstly, following the…
While a growing number of adults are now working at home for at least one or two days during the week, most children are now back in nurseries and classrooms from morning until the afternoon, five days a week. As a result, children were not spared by…
Paediatric analgesics saw only modest volume growth in 2023 as a result of a return to pre-pandemic consumption habits. More robust current value growth was partly the result of inflationary pressures due to the ongoing conflict in Ukraine, which has…
The pandemic led to a higher containment of flu and bronchiolitis in France due to prolonged home seclusion, which negatively impacted children’s immunity. The impact of this is becoming increasingly evident as young consumers now interact with one…
The re-opening of schools and the lifting of COVID-19 restrictions, such as compulsory use of face masks in schools, is leading to strong growth for multiple categories within paediatric consumer health. For example, sales of lice/anti-parasitic…
Paediatric consumer health is performing well in 2023 for the second consecutive year, albeit at a much lower pace of current value growth than in 2022. Ireland witnessed a more intense season of common colds and viruses among children in 2022 as the…
Paediatric consumer health is expected to see strong growth in current value terms in 2023, with most categories projected to post a positive performance in value and volume terms. Volume sales are benefiting from the increase in unit prices…
The sales performances recorded in each of the categories that comprise paediatric consumer health during 2023 were determined to some extent by the performances recorded in each of these categories in 2020, during the early stages of the COVID-19…
Over 2023, paediatric consumer health retail current value sales are expected to continue to grow healthily. On the other hand, retail volume development is projected to be marginal-to-moderate, with declines anticipated for paediatric acetaminophen…
Sales of sleep aids are seeing more stable growth in 2023 after the peaks achieved in 2020-2021 when the pandemic created widespread anxiety and insomnia. Many people had to work from home and home-school their children during times of lockdown and…
Sleep aids is expected to register moderate current value growth and a slight increase in volume sales in 2023. The war in Ukraine and the resulting energy crisis are pushing up average retail prices. While Danes are now much less concerned about the…
Demand for sleep aids remains high in 2023. Since the pandemic, an increase in sleep issues due to anxiety, depression, and stress, has spread among a large proportion of the French population. According to Euromonitor International’s Voice of the…
The key growth driver in sleep aids in terms of ingredients is melatonin. The variety and availability of products based on melatonin increased dramatically at the end of the review period. The launch of Procter & Gamble’s ZzzQuil Nature made a…
General anxiety related to economic uncertainty, the high cost of living and the war in Ukraine is improving the popularity of sleep aids in 2023. Many consumers are also back to hectic everyday lifestyles, with commuting, longer working hours and a…